Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiviral Therapy for Hepatitis C.

Michelle M. Lipman1, Scott J. Cotler

  • 1Rush University Medical Center, 1725 West Harrison Street, Suite 206, Chicago, IL 60612, USA. michelle_m_lipman@rush.edu

Current Treatment Options in Gastroenterology
|October 31, 2003
PubMed
Summary

Current hepatitis C virus (HCV) treatment involves pegylated interferon and ribavirin. Optimal response depends on HCV genotype, viral load, and cirrhosis absence, guiding tailored therapy duration and dosage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025
Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023
Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023
Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023
Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023
Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Current standard treatment for hepatitis C virus (HCV) infection utilizes pegylated interferon and ribavirin.
  • Key predictors of successful antiviral therapy include HCV genotype (2 or 3), low baseline viral load (<2 million copies/mL), and absence of cirrhosis.

Purpose of the Study:

  • To outline optimal treatment strategies for hepatitis C virus infection based on patient-specific factors.
  • To guide clinicians on necessary baseline assessments and treatment adjustments for maximizing patient response.

Main Methods:

  • Assessment of hepatitis C virus genotype and baseline viral load prior to therapy initiation.
  • Utilizing liver biopsy for disease staging, prognostication, and evaluation of coexisting liver injuries.
  • Tailoring treatment duration (24 or 48 weeks) and ribavirin dosage (800 mg/d or 1000-1200 mg/d) based on HCV genotype.

Main Results:

  • Patients with genotype 1 HCV require 48 weeks of therapy with higher ribavirin dosage for optimal response.
  • Patients with genotype 2 or 3 HCV benefit from shorter treatment duration (24 weeks) and lower ribavirin dosage.
  • Discontinuation of therapy is recommended if a 100-fold reduction in HCV RNA is not achieved by week 12, indicating a low likelihood of sustained response.

Conclusions:

  • Hepatitis C virus treatment efficacy is significantly influenced by genotype, baseline viral load, and liver disease status.
  • Personalized treatment regimens, including duration and dosage, are crucial for optimizing outcomes in HCV infection.
  • Liver transplantation evaluation is indicated for patients with advanced liver disease, decompensation, or early hepatocellular carcinoma.

Related Experiment Videos